Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.